DE69902037D1 - 3,3-diphenylpropylaminderivate - Google Patents

3,3-diphenylpropylaminderivate

Info

Publication number
DE69902037D1
DE69902037D1 DE69902037T DE69902037T DE69902037D1 DE 69902037 D1 DE69902037 D1 DE 69902037D1 DE 69902037 T DE69902037 T DE 69902037T DE 69902037 T DE69902037 T DE 69902037T DE 69902037 D1 DE69902037 D1 DE 69902037D1
Authority
DE
Germany
Prior art keywords
compounds
novel
preparation
methods
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69902037T
Other languages
English (en)
Other versions
DE69902037T2 (de
Inventor
Claus Meese
Bengt Sparf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
UCB Pharma GmbH
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8231918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69902037(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Pharma GmbH, Schwarz Pharma AG filed Critical UCB Pharma GmbH
Application granted granted Critical
Publication of DE69902037D1 publication Critical patent/DE69902037D1/de
Publication of DE69902037T2 publication Critical patent/DE69902037T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
DE69902037T 1998-05-12 1999-05-11 3,3-diphenylpropylaminderivate Expired - Lifetime DE69902037T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98108608A EP0957073A1 (de) 1998-05-12 1998-05-12 3,3-Diphenylpropylaminderivate
PCT/EP1999/003212 WO1999058478A1 (en) 1998-05-12 1999-05-11 Novel derivatives of 3,3-diphenylpropylamines

Publications (2)

Publication Number Publication Date
DE69902037D1 true DE69902037D1 (de) 2002-08-08
DE69902037T2 DE69902037T2 (de) 2003-02-06

Family

ID=8231918

Family Applications (2)

Application Number Title Priority Date Filing Date
DE122007000065C Active DE122007000065I2 (de) 1998-05-12 1999-05-11 3,3-diphenylpropylaminderivate
DE69902037T Expired - Lifetime DE69902037T2 (de) 1998-05-12 1999-05-11 3,3-diphenylpropylaminderivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE122007000065C Active DE122007000065I2 (de) 1998-05-12 1999-05-11 3,3-diphenylpropylaminderivate

Country Status (32)

Country Link
US (6) US6713464B1 (de)
EP (3) EP0957073A1 (de)
JP (3) JP3929702B2 (de)
KR (1) KR100599004B1 (de)
CN (2) CN1207268C (de)
AT (1) ATE220056T1 (de)
AU (1) AU748057B2 (de)
BR (1) BRPI9910406B8 (de)
CA (1) CA2328920C (de)
CY (1) CY2007024I1 (de)
CZ (2) CZ296605B6 (de)
DE (2) DE122007000065I2 (de)
DK (1) DK1077912T3 (de)
ES (1) ES2181443T3 (de)
FR (1) FR07C0050I2 (de)
GE (1) GEP20084461B (de)
HK (2) HK1046269B (de)
HU (2) HU230434B1 (de)
IL (1) IL139110A0 (de)
IS (1) IS2044B (de)
LU (1) LU91365I2 (de)
MX (1) MXPA00011096A (de)
NL (1) NL300293I2 (de)
NO (2) NO326872B1 (de)
NZ (1) NZ507487A (de)
PL (3) PL202489B1 (de)
PT (1) PT1077912E (de)
RU (1) RU2199525C2 (de)
SK (1) SK286052B6 (de)
TR (1) TR200003319T2 (de)
WO (1) WO1999058478A1 (de)
ZA (1) ZA200005728B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (de) 1998-05-12 1999-11-17 Schwarz Pharma Ag 3,3-Diphenylpropylaminderivate
DE19955190A1 (de) * 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) * 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
DE10315878B4 (de) 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
BRPI0409653A (pt) 2003-04-25 2006-04-25 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica
US7141696B2 (en) 2003-05-23 2006-11-28 Bridge Pharma, Inc. Smooth muscle spasmolytic agents
WO2005012227A2 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
WO2007039918A1 (en) * 2005-10-06 2007-04-12 Natco Pharma Limited Novel process for the preparation of tolterodine
EP1965863A2 (de) * 2005-12-20 2008-09-10 Pfizer Products Inc. Pharmazeutische kombination zur behandlung von luts mit einem pde5-hemmer und einem muscarinischen antagonisten
US8119667B2 (en) * 2005-12-29 2012-02-21 Schering-Plough Animal Health Corporation Carbonates of fenicol antibiotics
DK2029567T3 (da) * 2006-05-24 2010-11-29 Pfizer Ltd Fremgangsmåde til frembringelse af benzopyran-2-ol-derivater
EP1862449A1 (de) * 2006-05-31 2007-12-05 Schwarz Pharma Ltd. Verkürzte Synthese von substituierten Hydroxymethylphenolen
MX2008015233A (es) * 2006-05-31 2008-12-12 Schwarz Pharma Ltd Sintesis nueva de fenoles de hidroximetileno subtituidos.
IES20060424A2 (en) 2006-06-08 2007-10-31 Schwarz Pharma Ltd Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters
WO2007140986A1 (en) * 2006-06-09 2007-12-13 Schwarz Pharma Ltd Synthesis of phenolic esters of hydroxymethyl phenols
NZ572616A (en) * 2006-06-09 2010-11-26 Sanol Arznei Schwarz Gmbh Stabilized pharmaceutical compositions comprising fesoterodine
US7807715B2 (en) 2006-06-09 2010-10-05 Ucb Pharma Gmbh Pharmaceutical compositions comprising fesoterodine
IES20060435A2 (en) 2006-06-12 2007-12-12 Schwarz Pharma Ltd Shortened synthesis using paraformaldehyde or trioxane
KR20140010198A (ko) * 2006-06-12 2014-01-23 유씨비 파마 게엠베하 새로운 키랄 중간체, 그 키랄 중간체의 제조방법 및 톨테로딘, 페소테로딘 또는 그 활성대사물질의 제조에서 그 키랄 중간체의 사용
CZ298448B6 (cs) * 2006-08-09 2007-10-03 Zentiva, A. S. Farmaceutická kompozice s obsahem tolterodinu
JP4859255B2 (ja) * 2006-11-17 2012-01-25 旭化成ケミカルズ株式会社 イソシアネートの製造方法
TW200844080A (en) 2007-01-11 2008-11-16 Asahi Kasei Chemicals Corp Process for producing isocyanate
WO2008144602A1 (en) * 2007-05-18 2008-11-27 Auspex Pharmaceuticals, Inc. Deuterated zamifenacin derivatives
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US20090062398A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched tolterodine
US20090062385A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched fesoterodine
WO2009037569A2 (en) * 2007-09-21 2009-03-26 Actavis Group Ptc Ehf An improved process for the preparation of fesoterodine
WO2009044278A1 (en) * 2007-10-01 2009-04-09 Actavis Group Ptc Ehf Amorphous fesoterodine fumarate
TWI446904B (zh) * 2007-11-01 2014-08-01 Acucela Inc 用於治療眼科疾病及病症之胺衍生化合物
WO2009122303A2 (en) * 2008-04-04 2009-10-08 Actavis Group Ptc Ehf Novel mandelate salt of fesoterodine
EP2275406B1 (de) 2008-05-15 2018-11-28 Asahi Kasei Kabushiki Kaisha Verfahren zur herstellung von isocyanat
RU2523201C2 (ru) 2008-05-15 2014-07-20 Асахи Касеи Кемикалз Корпорейшн Способ получения изоцианатов с использованием диарилкарбоната
EP2323967A2 (de) * 2008-07-21 2011-05-25 Actavis Group PTC EHF Fesoterodin, das eine reduzierte menge an dehydroxyfesoterodin enthält
JP5381086B2 (ja) * 2008-10-06 2014-01-08 日本電気株式会社 通信システム及び通信制御方法
ES2533956T3 (es) 2009-05-11 2015-04-16 Ratiopharm Gmbh Desfesoterodina en forma de una sal de ácido tartárico
IT1394217B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
IT1394219B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina fumarato di elevata purezza.
EP2281801B1 (de) 2009-07-27 2014-01-08 Crystal Pharma, S.A.U. Verfahren zur Herstellung von 3,3-Diphenylpropylaminen
IT1396373B1 (it) 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20110124903A1 (en) * 2009-11-20 2011-05-26 Actavis Group Ptc Ehf Solid state forms of fesoterodine intermediates
IT1397521B1 (it) * 2009-12-21 2013-01-16 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina con un basso contenuto di impurezze.
EP2364966A1 (de) 2010-03-09 2011-09-14 LEK Pharmaceuticals d.d. Verfahren zur Herstellung von 3-(2-hydroxy-5-substituierten phenyl)-3-phenylpropylaminen, Zwischenprodukte zur Herstellung von Hydroxytolterodin
WO2011117884A1 (en) 2010-03-22 2011-09-29 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
ES2604705T3 (es) 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Agente preventivo y/o remedio para el síndrome mano-pie
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
WO2011141932A2 (en) 2010-05-11 2011-11-17 Intas Pharmaceuticals Limited Process for preparation of phenolic monoesters of hydroxymethyl phenols
IT1401451B1 (it) * 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
WO2011158257A1 (en) 2010-06-18 2011-12-22 Panacea Biotec Ltd Preparation process of fesoterodine and intermediates
WO2012025941A2 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Processes for the preparation of fesoterodine
US8501796B2 (en) * 2010-09-16 2013-08-06 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
IT1403094B1 (it) 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
WO2012098560A2 (en) * 2011-01-17 2012-07-26 Msn Laboratories Limited Process for the preparation of muscarinic receptor antagonist
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
US9085509B2 (en) 2011-04-07 2015-07-21 Alembic Pharmaceuticals Limited Process for preparing fesoterodine
EP2508175A1 (de) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmazeutische Zusammensetzung enthaltend Fesoterodin oder ein Salz oder ein Solvat davon
EP2508173A1 (de) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabile pharmazeutische Zusammensetzung mit Fesoterodin
WO2013021343A1 (en) 2011-08-05 2013-02-14 Ranbaxy Laboratories Limited Process for the optical resolution of () -3- (2 -benzyloxy- 5 - bromophenyl) - 3 - phenylpropionic
WO2013046135A1 (en) 2011-09-26 2013-04-04 Ranbaxy Laboratories Limited Process for the preparation of fesoterodine or its salts
EP2800735B1 (de) 2012-01-07 2016-03-30 Alembic Pharmaceuticals Limited Verfahren zur herstellung von fesoterodin
CN103304356B (zh) * 2012-03-12 2016-01-20 北京乐威泰克医药技术有限公司 羟胺的合成方法
JP6234999B2 (ja) 2012-05-04 2017-11-22 クリスタル ファルマ、エセ、ア、ウＣｒｙｓｔａｌ Ｐｈａｒｍａ，Ｓ．Ａ．Ｕ． 光学的に活性な３，３−ジフェニルプロピルアミンを調製するための方法
WO2013046194A2 (en) 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
EP2760822B1 (de) 2012-06-14 2016-03-23 ratiopharm GmbH Desfesoterodinsalze
ITMI20121232A1 (it) * 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
US9751828B2 (en) 2014-07-30 2017-09-05 Dipharma Francis S.R.L. Antimuscarinic compound having a low content of impurities
TR201721437A2 (tr) 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE766207C (de) 1940-07-08 1952-12-22 Ig Farbenindustrie Ag Verfahren zur Herstellung von basischen Verbindungen der Diarylmethanreihe
DE925468C (de) 1941-08-13 1955-03-21 Hoechst Ag Verfahren zur Herstellung von ª†, ª†-Diaryl-propyl-aminen
GB624117A (en) 1946-12-07 1949-05-27 Wellcome Found Improvements in and relating to the preparation of substituted allylamines and propylamines
GB627139A (en) 1947-05-28 1949-07-29 Wellcome Found Improvements in and relating to the preparation of quaternary ammonium salts of substituted propanolamines, allylamines and propylamines
NL70759C (de) 1947-10-28
US2567245A (en) 1948-05-10 1951-09-11 Schering Corp Aryl-(2-pyridyl)-amino alkanes and their production
US2556636A (en) 1948-06-23 1951-06-12 Schering Corp gamma-substituted propylamine type antihistamines
DE830193C (de) 1948-11-09 1952-02-04 Farbwerke Hoechst Vormals Meis Verfahren zur Herstellung von basischen Verbindungen
CH285389A (de) 1948-11-09 1952-08-31 Michael Dr Erlenbach Verfahren zur Herstellung einer basischen Verbindung.
GB685696A (en) 1948-11-23 1953-01-07 Schering Corp Process for the manufacture of anti-histaminic compounds
NL74271C (de) 1949-09-05
US2676964A (en) 1950-06-07 1954-04-27 Schering Corp 3-pyridyl propylamine antihistamine substances
US3261841A (en) 1961-05-03 1966-07-19 Sterling Drug Inc N-substituted 1,5-iminocycloalkanes and -alkenes
US3216841A (en) * 1962-04-30 1965-11-09 Clevite Corp Metal slip casting composition
DK111894A (de) 1962-11-15
GB1025041A (en) 1964-02-21 1966-04-06 Hoechst Ag Process for the manufacture of diphenylalkylamines
GB1169945A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
GB1169944A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Novel 3,3-Diphenylpropylamines and processes for the preparation thereof
HU200591B (en) 1986-07-11 1990-07-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5693144A (en) * 1990-03-19 1997-12-02 3D Systems, Inc. Vibrationally enhanced stereolithographic recoating
MX9302812A (es) 1992-05-13 1993-11-01 Alza Corp Administracion transdermica de oxibutinina.
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU7994694A (en) 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
AU728395B2 (en) 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
CA2274832A1 (en) 1996-12-12 1998-06-18 Dds Drug Delivery Service Gesellschaft Zur Forderung Der Forschung In Ph Armazeutischer Technologie Und Biopharmazie Mbh Preparation in form of a matrix material-auxiliary agent compound containing optionally an active substance
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
SE9701144D0 (sv) 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0872233A1 (de) 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretrovirale Arzneimittel mit verbesserter Bioverfügbarkeit
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
EP0957073A1 (de) * 1998-05-12 1999-11-17 Schwarz Pharma Ag 3,3-Diphenylpropylaminderivate
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
CZ302630B6 (cs) 1998-08-27 2011-08-10 Pharmacia & Upjohn Ab Farmaceutický prostredek obsahující tolterodin nebo tolterodinu príbuznou slouceninu
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
SK6412002A3 (en) 1999-11-11 2002-09-10 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
DE19955190A1 (de) 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
US6566537B2 (en) 1999-12-30 2003-05-20 Pharmacia Ab Process and intermediates
DE10028443C1 (de) 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
US20030086972A1 (en) 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AR033711A1 (es) 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
US20030027856A1 (en) 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
GB0117619D0 (en) 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
PL370539A1 (en) 2001-09-04 2005-05-30 Pfizer Inc. Assay
JP2005506323A (ja) 2001-09-05 2005-03-03 ベクトゥラ・リミテッド 経口送達用機能性散剤
BR0212824A (pt) 2001-09-27 2004-10-13 Pharmacia Ab Composição farmacêutica
ATE418534T1 (de) 2001-10-26 2009-01-15 Pharmacia & Upjohn Co Llc Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe
CA2464217A1 (en) 2001-11-05 2003-05-15 Pharmacia & Upjohn Company Antimuscarinic aerosol
WO2003053428A1 (en) 2001-12-20 2003-07-03 Pharmacia Corporation Controlled release dosage form having improved drug release properties
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
DE10224107A1 (de) 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
AU2003236947A1 (en) 2002-06-07 2003-12-22 Ranbaxy Laboratories Limited Modified release, multiple unit drug delivery systems
ITMI20021329A1 (it) 2002-06-14 2003-12-15 Recordati Chem Pharm Nuove ossialchilammine sostituite
WO2004019892A2 (en) 2002-08-30 2004-03-11 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
WO2004031973A1 (en) 2002-09-30 2004-04-15 Advent Networks, Inc. Implementing request/reply programming semantics using publish/subscribe middleware
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
BRPI0409653A (pt) 2003-04-25 2006-04-25 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica

Also Published As

Publication number Publication date
PL218882B1 (pl) 2015-02-27
US7384980B2 (en) 2008-06-10
NL300293I2 (nl) 2008-03-03
IS2044B (is) 2005-09-15
NL300293I1 (nl) 2007-11-01
NZ507487A (en) 2002-11-26
KR100599004B1 (ko) 2006-07-12
EP0957073A1 (de) 1999-11-17
JP2003519079A (ja) 2003-06-17
BR9910406B1 (pt) 2014-01-07
PL195581B1 (pl) 2007-10-31
US7855230B2 (en) 2010-12-21
PT1077912E (pt) 2002-11-29
US20040186061A1 (en) 2004-09-23
NO20005669D0 (no) 2000-11-10
EP1254890A1 (de) 2002-11-06
CA2328920C (en) 2008-04-15
DE69902037T2 (de) 2003-02-06
AU748057B2 (en) 2002-05-30
JP3929702B2 (ja) 2007-06-13
ES2181443T3 (es) 2003-02-16
HK1046269A1 (en) 2003-01-03
US20110294882A1 (en) 2011-12-01
SK15472000A3 (sk) 2001-06-11
BRPI9910406B8 (pt) 2021-05-25
CN1207268C (zh) 2005-06-22
KR20010082547A (ko) 2001-08-30
JP2007084552A (ja) 2007-04-05
NO2009015I2 (no) 2012-11-12
JP2007204481A (ja) 2007-08-16
US6713464B1 (en) 2004-03-30
ATE220056T1 (de) 2002-07-15
US20100256231A1 (en) 2010-10-07
HU226490B1 (en) 2009-03-02
HK1046269B (zh) 2005-09-23
JP4658895B2 (ja) 2011-03-23
US8338478B2 (en) 2012-12-25
AU4141299A (en) 1999-11-29
IS5670A (is) 2000-10-17
CN1354737A (zh) 2002-06-19
US7230030B2 (en) 2007-06-12
LU91365I2 (fr) 2007-11-14
CZ299721B6 (cs) 2008-10-29
HK1084099A1 (en) 2006-07-21
CN100491336C (zh) 2009-05-27
ZA200005728B (en) 2001-03-05
US20060270738A1 (en) 2006-11-30
US20090042981A1 (en) 2009-02-12
MXPA00011096A (es) 2002-06-04
DE122007000065I1 (de) 2008-01-03
FR07C0050I2 (de) 2008-05-09
US7985772B2 (en) 2011-07-26
HUP0100779A3 (en) 2002-11-28
FR07C0050I1 (de) 2007-11-16
CN1690041A (zh) 2005-11-02
HU230434B1 (hu) 2016-06-28
BR9910406A (pt) 2001-01-09
JP4833884B2 (ja) 2011-12-07
EP1077912A1 (de) 2001-02-28
CA2328920A1 (en) 1999-11-18
IL139110A0 (en) 2001-11-25
DK1077912T3 (da) 2002-10-28
CY2007024I2 (el) 2010-07-28
CZ296605B6 (cs) 2006-04-12
NO2009015I1 (no) 2009-07-17
GEP20084461B (en) 2008-08-25
CY2007024I1 (el) 2010-07-28
PL202489B1 (pl) 2009-06-30
LU91365I9 (de) 2018-12-31
DE122007000065I2 (de) 2010-03-25
HU0600760D0 (en) 2006-12-28
EP1077912B1 (de) 2002-07-03
NO20005669L (no) 2001-01-11
SK286052B6 (sk) 2008-02-05
NO326872B1 (no) 2009-03-09
HUP0100779A2 (hu) 2001-08-28
WO1999058478A1 (en) 1999-11-18
RU2199525C2 (ru) 2003-02-27
PL347823A1 (en) 2002-04-22
CZ20003774A3 (cs) 2001-03-14
TR200003319T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
DE69902037D1 (de) 3,3-diphenylpropylaminderivate
IL112880A0 (en) 9-deoxotaxane compounds
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
DE69902535T2 (de) Phenoxypropanolamin-derivate, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen zusammensetzungen
LU91761I2 (fr) Vernakalant et ses dérivés pharmaceutiquement acceptables et en particulier son sel d'hydrochlorure (BRINAVESS®)
BR9707064A (pt) Novos derivados 19-nor-pregneno
EE200000014A (et) (+)-nortsisapriidaluse valmistamismeetod, (+)-nortsisapriid, selle farmatseutiliselt vastuvõetav happe liitsool ja nende kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod ning vaheühend
ATE247645T1 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
IL163608A (en) Sulfonanilides are conserved in their amino / amino acids and derivatives, their process, their pharmaceutical preparations, and their conjugated antibodies and their use in the preparation of drugs for the treatment of culture disorders
WO1999058490A3 (en) Novel aryl-hydro naphthalenal kanamines
DZ3096A1 (fr) Procédé pour la préparation de dérivés de pyrazoloÄ4,3-DÜpyrimidine-7-one-3-pyridylsulfonyle, et intermédiaires utilisés.
DE60220800D1 (de) Chirales dinapsolin
CA2235053A1 (fr) Nouveaux composes amines du 6,7,8,9-tetrahydro-cyclopenta¬a|naphtalene et du 2,3-dihydro-cyclopenta, ¬e|indene, leur procede de preparation et les compositions pharmaceutiques quiles contiennent
ATE11530T1 (de) P-chlorophenoxyessigsaeure-derivat, verfahren zu dessen herstellung und pharmazeutische zusammenstellung.
DE69104058T2 (de) N-[(2-thenoylmerkapto-3-methyl)-butanoyl]-homocysteinthiolacton, verfahren zu seiner herstellung und diese enthaltende pharmaceutische zusammensetzungen.
HUT57746A (en) Process for producing new 1,3-oxazines and pharmaceutical compositions comprising same
HK56797A (en) Ethanolamine-benzoate derivative process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: FESOTERODINE UND SEINE SALZE MIT PHYSIOLOGISCH ANNEHMBAREN SAEUREN; REGISTRATION NO/DATE: EU/1/07/386/001 - EU/1/07/386/010; 20070420

Spc suppl protection certif: 12 2007 000 065

Filing date: 20071010

Free format text: PRODUCT NAME: FESOTERODINFUMARAT; REGISTRATION NO/DATE: EU/1/07/386/001 - EU/1/07/386/010; 20070420

Spc suppl protection certif: 12 2007 000 065

Filing date: 20071010

V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: FESOTERODINFUMARAT; REGISTRATION NO/DATE: EU/1/07/386/001 - EU/1/07/386/010; 20070420

Spc suppl protection certif: 12 2007 000 065

Filing date: 20071010

V457 Spc granted

Free format text: PRODUCT NAME: FESOTERODINFUMARAT; REGISTRATION NO/DATE: EU/1/07/386/001 - EU/1/07/386/010; 20070420

Spc suppl protection certif: 12 2007 000 065

Filing date: 20071010

8327 Change in the person/name/address of the patent owner

Owner name: UCB PHARMA GMBH, 40789 MONHEIM, DE